Baolingbao Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as "Baolingbao" or "the Company") and all members of the Board of Directors guarantee that the content of this announcement is true, accurate, and complete, with no false records, misleading statements, or major omissions.
On May 29, 2026, Baolingbao held the 18th meeting of the 6th Board of Directors, during which the proposals for the re-election of the Chairman of the 6th Board of Directors and the Head of the Strategic Committee were approved. The relevant information is announced as follows:
1. Resignation of the Chairman
On May 29, 2026, the Board of Directors received a report from Mr. Wang Qiang, the Chairman and General Manager, regarding his resignation from the position of Chairman. Mr. Wang applied to resign from the positions of Chairman and Head of the Strategic Committee to focus on the overall management of the Company. After resigning from these positions, Mr. Wang will continue to serve as a director, general manager, and member of the Compensation and Assessment Committee. The Board expresses heartfelt gratitude for Mr. Wang's significant contributions to the Company's strategic development and stable operations during his tenure as Chairman.